A Study to Evaluate CG-105-12 in Patients With Relapsed/Refractory Multiple Myeloma

This study is testing a new CAR-T cell therapy called CG-105-12 for people with multiple myeloma — a cancer of the blood — that has come back or stopped responding to other treatments. **You may be eligible if...** - You are 18–75 years old - You have had at least 3 prior treatments for multiple myeloma (including both a proteasome inhibitor and an immunomodulatory drug) - Your myeloma has come back or is no longer responding to treatment - Lab tests show your cancer cells carry a protein called BCMA - You have never received CAR-T cell therapy targeting BCMA before - Your overall health is reasonably good (able to carry out daily activities) **You may NOT be eligible if...** - You have active hepatitis B, hepatitis C, HIV, or syphilis - You have had certain other cancers in the past 5 years - You have had an organ transplant or prior bone marrow transplant from a donor - You have uncontrolled infections, severe heart disease, or uncontrolled diabetes - You are pregnant or breastfeeding - You have had certain recent treatments (e.g., recent chemotherapy, steroids, or live vaccines) Talk to your doctor to see if this trial is right for you.